Clinical Trials Logo

Disorder of Transplanted Kidney clinical trials

View clinical trials related to Disorder of Transplanted Kidney.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02902120 Completed - Hepatitis C Clinical Trials

HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant

Start date: May 1, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether patients treated for chronic hepatitis C (HCV) with zepatier (grazoprevir/elbasvir) prior to kidney transplant will have a stronger immune response compared to patients treated after kidney transplant. 25 patients with chronic kidney disease (CKD) and HCV will be treated with zepatier and 25 kidney transplant recipients with chronic kidney disease will be treated with zepatier. Blood markers of immune function will be monitored in both groups to determine their response to therapy.

NCT ID: NCT02017990 Completed - Clinical trials for Disorder of Transplanted Kidney

Plasma Marine n-3 Polyunsaturated Fatty Acids and Patient and Graft Survival

Start date: October 1999
Phase: N/A
Study type: Observational

This study will evaluate the association between n-3 polyunsaturated fatty acids and patient and graft survival. The association between other fatty acids and mortality and graft loss endpoints will also be evaluated.

NCT ID: NCT01436747 Completed - Proteinuria Clinical Trials

Efficacy and Safety of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients

Start date: July 2012
Phase: Phase 3
Study type: Interventional

The study 'Safety and Efficacy of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients' is designed to assess the effects of paricalcitol in kidney transplant recipients with proteinuria. It is a single centre, randomized, placebo-controlled, double-blind clinical trial that tests the hypothesis that 24 weeks' treatment with paricalcitol compared to placebo will result in a decrease in urinary protein excretion in recipients of a kidney transplant at least three months after transplantation. Additionally, the effects of paricalcitol on albuminuria, estimated glomerular filtration rate, and blood pressure will be investigated.